Post highlights: -What “metabolically healthy” really means -Why metabolic health affects energy, appetite, and long-term wellbeing -How modern meals can place stress on metabolism -Signs of healthy metabolic function -Simple habits that support metabolic health -How supporting steadier post-meal responses may help maintain metabolic balance
Modern food is designed for speed, taste, and convenience. It is not designed around how the body processes energy. Many meals today are rich in carbohydrates and fats that are broken down and absorbed very quickly. When energy enters the system rapidly, it can lead to sharp rises after eating followed by dips later on.
Those dips are familiar to many people. You eat lunch, feel fine at f
Stockholm — January 21, 2026 — Sigrid Therapeutics (Sigrid) is a Swedish-based, science-driven consumer health company with a primary focus on metabolic health. Following the successful launch of its first two clinically proven products — Carb Fence , developed to support weight loss by reducing appetite and sugar cravings while promoting fat loss and preserving muscle mass , and Glucose Stabi
Sigrid, a Swedish innovation company in consumer health, today announces that the company has raised SEK 45 million in new capital.
After an exceptionally successful online launch earlier this year, Sigrid Therapeutics and Kronans Apotek are now ready to take the next step: SIGRID Stabiliser will be launched on store shelves across the country in the fall of 2025.
SIGRID, the Swedish innovative consumer health company behind the patented SiPore® technology, today reports new clinical and commercial milestones for its innovative dietary supplement Glucose Stabiliser.
Sigrid Therapeutics (Sigrid) today announced that it has secured U.S. marketing approval for its patented SiPore® technology, following the successful SHINE study, the largest study of its kind in prediabetes.
Sigrid Therapeutics announced today that the company has recruited over 50% of patients in SHINE, a clinical trial evaluating SiPore21® for the treatment of elevated glucose levels.
Sigrid Therapeutics is pleased to announce the start of the SHINE clinical trial for SiPore21® – an innovative medical device designed for long-term maintenance of blood sugar and weight control.
Sigrid Therapeutics, a Swedish consumer-focused technology company in consumer health, announced today that an additional SEK 10.6 million has been added to the company to accelerate the commercialization of its portfolio of dietary supplements based on SiPore®.
Sigrid Therapeutics, a technology company specializing in the prevention of type 2 diabetes and obesity, announced today that the company has been granted a patent by the United States Patent and Trademark Office (USPTO).
Sigrid Therapeutics announced today that the Company has been named by FierceMedTech as one of the 2019 “Fierce 15” companies, one of the most promising private medtech companies in the industry. This is the first time in its eight-year history that a Swedish company has been included on the list.
Sigrid Therapeutics reports significant blood sugar reduction and excellent safety profile in the STAR study with SiPore15, a groundbreaking medical device for prediabetes and untreated type 2 diabetes
Sigrid Therapeutics AB, an innovative technology company developing a new class of products to improve human health, including type 2 diabetes, today announces that it has closed a rights issue of SEK 15.5 million.
Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies in metabolic diseases, today announces that all patients have completed treatment with SiPore15 in the STAR clinical trial.
At Almi Invest's 10th anniversary on May 28 at Nalen in Stockholm, Sigrid's CEO and Co-Founder Sana Alajmovic won the jury and audience's favor in the Startup Pitch of the Year competition.
The leading international life science journal Genetic Engineering News (GEN) has selected Sana Alajmovic, CEO of Sigrid Therapeutics, to this year's highly prestigious Top 10 Under 40 list 2019.
Sigrid Therapeutics today announced the publication of a large study in mice in the peer-reviewed journal Nanomedicine. The study demonstrates enzyme-blocking effects of mesoporous silica particles (MSPs) administered into the intestine with effects on food efficiency and metabolic risk factors as a result.